Nephrology, dialysis and apheresis unit, University of Montpellier-Nimes, CHU de Nîmes, Rue du Professeur Robert Debré, Nîmes, France.
Laboratory of anatomopathology, University of Montpellier-Nimes, CHU de Montpellier, Montpellier, France.
BMC Nephrol. 2020 May 24;21(1):196. doi: 10.1186/s12882-020-01856-z.
The kidney is a major target in primary antiphospholipid syndrome. Several types of nephropathy have been reported, the most frequent being acute or chronic specific vascular nephropathies and membranous nephropathy.
A 59-year-old male presented in our unit with nephrotic syndrome. He had a history of primary antiphospholipid syndrome with lupus anticoagulant treated with vitamin K antagonist therapy. On admission, antiphospholipid (lupus anticoagulant) and anti-PLA2R antibodies were positive. Screening for secondary etiologies was negative. In the context of primary antiphospholipid syndrome treated with vitamin K antagonist therapy, we did not perform a biopsy and we treated the patient with angiotensin-converting-enzyme inhibitor. No remission was observed at 6 months with persistent anti-PLA2R antibodies while antiphospholipid antibody level became negative. Consequently, kidney biopsy was performed showing both membranous nephropathy with PLA2R in deposits on immunohistochemistry with IgG4 dominance and antiphospholipid syndrome chronic vascular nephropathy. Following that, treatment with rituximab was started with secondarily a decrease in serum PLA2R antibody levels and partial remission.
We report the first association between primary antiphospholipid syndrome and membranous nephropathy with anti-PLA2R antibodies. Our observations could suggest a causal link between primary antiphospholipid syndrome and PLA2R-related membranous nephropathy. Consequently, it would be interesting to screen for anti-PLA2R antibodies for further cases of nephrotic syndrome in patients with primary antiphospholipid syndrome and to search antiphospholipid antibodies in all membranous nephropathies.
肾脏是原发性抗磷脂综合征的主要靶器官。已有多种类型的肾病报道,最常见的是急性或慢性特异性血管性肾病和膜性肾病。
一名 59 岁男性因肾病综合征就诊于我院。他患有原发性抗磷脂综合征,伴有狼疮抗凝物,曾接受维生素 K 拮抗剂治疗。入院时,抗磷脂(狼疮抗凝物)和抗-PLA2R 抗体阳性。排除了继发性病因。在接受维生素 K 拮抗剂治疗的原发性抗磷脂综合征背景下,我们未进行肾活检,给予患者血管紧张素转换酶抑制剂治疗。6 个月时,尽管抗-PLA2R 抗体持续存在,但未观察到缓解,而抗磷脂抗体水平转为阴性。因此,进行了肾活检,免疫组化显示 IgG4 优势的 PLA2R 沉积的膜性肾病和抗磷脂综合征慢性血管性肾病。此后,开始使用利妥昔单抗治疗,随后血清 PLA2R 抗体水平下降,病情部分缓解。
我们报告了首例原发性抗磷脂综合征与抗-PLA2R 抗体相关的膜性肾病之间的关联。我们的观察结果提示原发性抗磷脂综合征与 PLA2R 相关膜性肾病之间可能存在因果关系。因此,对于原发性抗磷脂综合征伴肾病综合征的患者,筛查抗-PLA2R 抗体以进一步明确诊断,并在所有膜性肾病患者中筛查抗磷脂抗体可能会很有趣。